Human PON promoters: From similarity to prediction of polymorphic positions within transcription factor elements

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 10, 2010, Pages 938-945

  Najafi, M ^a   Jangravi, Z ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Element; Polymorphism; PON; Promoter; Similarity; Transcription factor

Indexed keywords

ALANINE; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; CYSTEINE; ESTERASE; GLYCINE; KRUPPEL LIKE FACTOR; PAIRED BOX TRANSCRIPTION FACTOR; PROTEIN PON 3; THREONINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD SAMPLING; CHROMOSOME 7; DEMENTIA; DIABETES MELLITUS; DNA FLANKING REGION; DNA FRAGMENTATION; ENZYME ACTIVITY; GENE CLUSTER; GENE DUPLICATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PREDICTION; PROMOTER REGION; SEQUENCE ALIGNMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; TAXONOMY; VASCULAR DISEASE;

ARYLDIALKYLPHOSPHATASE; HUMANS; MULTIGENE FAMILY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION FACTORS;

EID: 77956687908     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710792007169     Document Type: Article

References (47)

1. Aviram, M.; Rosenblat, M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods. Mol. Biol., 2008, 477, 259-276.
2. La, Du, B.N. In: Human serum paraoxonase/arylesterase. Kalow, W.; Ed. Pharmacogenetics of Drug Metabolism. New York, NY: Pergamon Press, 1992, pp. 51-91.
3. Mackness, M.I.; Arrol, S.; Abbot, C.; Durrington, P.N. Protection of low density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis, 1993, 104, 129-135.
4. Watson, A.D.; Berliner, J.A.; Hama, S.Y.; La, Du, B.N.; Faull, K.F.; Fogelman, A.M.; Navab, M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest., 1995, 96, 2882-2891.
5. Li, H.L.; Liu, D.P.; Liang, C.C. Paraoxonas gene polymorphisms,oxidative stress and diseases. J. Mol. Med, 2003, 81, 766-779.
6. Ng, C.J.; Shih, D.M.; Hama, S.Y.; Villa, N.; Navab, M.; Reddy, S.T. The paraoxonase gene family and atherosclerosis. Free Radic. Biol. Med., 2005, 15,153-163.
7. Leviev, I.; James, R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 516-521.
8. Soran, H.; Younis, N.N.; Charlton-Menys, V.; Durrington, P. Variation in paraoxonase-1 activity and atherosclerosis. Curr. Opin. Lipidol., 2009, 20, 265-274.
9. Draganov, D.I.; La, Du, B.N. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedeberg's Arch. Pharmacol., 2004, l369, 8-88.
10. Durrington, P.N.; Mackness, B.; Mackness, M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 473-480.
11. Adkins, S.; Gan, K.N.; Mody, M.; La, Du, B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am. J. Hum. Genet., 1993, 52, 598-608.
12. Humbert, R.; Adler, D.A.; Disteche, C.M.; Hassett, C.; Omiecinski C.J.; Furlong, C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat. Genet., 1993, 3, 73-76.
13. Blatter, Garin, M.C.; James, R.W.; Dussoix, P.; Blanche, H.; Passa, P.; Froguel, P.; Ruiz, J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J. Clin. Invest., 1997, 99, 62-66.
14. Leviev, I.; Negro, F.; James, R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 2935-2939.
15. Mackness, B.; Mackness, M.I.; Arrol, S.; Turkie, W.; Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS. Lett., 1998, 423, 57-60.
16. Brophy, V.H.; Jampsa, R.L.; Clendenning, J.B.; McKinstry, L.A.; Jarvik, G.P.; Furlong, C.E. Effects of 5 regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am. J. Hum. Genet., 2001, 68, 1428-1436.
17. Brophy, V.H.; Hastings, M.D.; Clendenning, J.B.; Richter, R.J.; Jarvik, G.P.; Furlong, C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics, 2001, 11, 77-84.
18. Suehiro, T.; Nakamura, T.; Inoue, M.; Shiinoki, T.; Ikeda, Y.; Kumon, Y.; shindo M.; Tanaka, H.; Hashimoto, K. A polymorphism upstream from human paraoxonase (PON1) gene and association with PON1 experession. Atherorosclerosis, 2000, 150, 295-298.
19. Helbecque, N.; Cottel, D.; Codron, V.; Berr, C.; Amouyel, P. Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci. Lett., 2004, 18, 41-44.
20. Cellini, E.; Tedde, A.; Bagnoli, S.; Nacmias, B.; Piacentini, S.; Bessi, V.; Bracco, L.; Sorbi, S. Association analysis of the paraoxonase-1 gene with Alzheimer's disease. Neurosci. Lett., 2006, 20, 199-202.
21. Cronin, S.; Greenway, M.; Prehn, J.H.; Hardiman, O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry, 2007, 78, 984-986.
22. Morahan, J.M.; Yu, B.; Trent, R.J.; Pamphlett, R. A gene-environment study of the paraoxonase 1 gene and pesticides in amyotrophic lateral sclerosis. Neurotoxicology, 2007, 28, 532-540.
23. Kovács, T.J.; Harris, S.; Vas, T.K.; Seres, I.; Short, C.D.; Wittmann, I.K.; Paragh, G.; Mackness, M.I.; Mackness, B.; Durrington, P.N.; Nagy, J.M.; Brenchley, P.E. Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy. J. Nephrol., 2006, 19, 732-738.
24. Flekac, M.; Skrha, J.; Zídková, K.; Lacinová, Z.; Hilgertová, J. Paraoxonase 1 gene polymorphisms and enzyme activities in diabetes mellitus. Physiol. Res, 2008, 57, 717-726.
25. Hofer, S.E.; Bennetts, B.; Chan, A.K.; Holloway, B.; Karschimkus, C.; Jenkins, A.J.; Silink, M.; Donaghue, K.C. Association between PON1 polymorphisms, PON activity and diabetes complications. J. Diabetes. Complications, 2006, 20, 322-328.
26. James, R.W.; Leviev, I.; Ruiz, J.; Passa, P.; Froguel, P.; Garin, M.C. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes, 2000, 49, 1390-1393.
27. Leviev, I.; Poirier, O.; Nicaud, V.; Evans, A.; Kee, F.; Arveiler, D.; Morrisson, C.; Cambien, F.; James, R.W. High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis, 2002, 161, 463-467.
28. Wang, X.; Fan, Z.; Huang, J.; Su, S.; Yu, Q.; Zhao, J.; Hui, R.; Yao, Z.; Shen, Y.; Qiang, B.; Gu, D. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler. Thromb. Vasc Biol., 2003, 1, 328-334.
29. Ranade, K.; Kirchgessner, T.G.; Iakoubova, O.A.; Devlin, J.J.; DelMonte, T.; Vishnupad, P.; Hui, L.; Tsuchihashi, Z.; Sacks, F.M.; Sabatine, M.; Braunwald, E.; White, T.J.; Shaw, P.M.; Dracopoli, N.C. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke, 2005, 36, 2346-2350.
30. Deakin, S.; Leviev, I.; Brulhart-Meynet M.C.; James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position 107, implicating the Sp1 transcription factor. Biochem. J., 2003, 372, 643-649.
31. Su, S.Y.; Chen, J.H.; Huang, J.F.; Wang, X.L.; Zhao, J.G.; Shen, Y.; Qiang, B.Q.; Gu, D.F. Paraoxonase gene cluster variations associated with coronary heart diseases in Chinese Han women. Chin. Med. J., 2005, 118, 1167-1174.
32. Najafi, M.; Firoozrai, M.; Gohari, H.L.; Zavarehie, A.; Basiri, G. Direct haplotyping of bi-allelic SNPs using Arms and RFLP analysis techniques. Biomol. Eng., 2007, 24, 609-612.
33. Najafi, M.; Gohari, H.L.; Firoozrai, M. Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries. Thromb. Res., 2009, 123, 503-510.
34. Najafi, M.; Gohari, H.L.; Firoozrai, M.; Zavarehee, A.; Basiri H.A. Association between Paraoxonase -1 Gene Pro-moter T (-107) C Polymorphism and Coronary Artery Disease. Iranian. J. Public. Health., 2008, 37, 108-113.
35. Primo-Parmo, S.L.; Sorenson, R.; Teiber, J.; La, Du, B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics., 1996, 33, 498-507.
36. Ng, C.J.; Wadleigh, D.J.; Gangopadhyay, A.; Hama, S.; Grijalva, V.R.; Navab, M.; Fogelman, A.M.; Reddy, S.T. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem., 2001, 276, 44444-44449.
37. Chen, Q.; Reis, S.E.; Kammerer, C.M.; McNamara, D.M.; Holubkov, R.; Sharaf, B.L.; Sopko, G.; Pauly, D.F.; Merz, C.N.; Kamboh, M.I. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am. J. Hum. Genet., 2003, 72, 13-22.
38. Pan, J.P.; Lai, S.T.; Chiang, S.C.; Chou, S.C.; Chiang, A.N. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi. (Taipei), 2002, 65,415-421.
39. Martinelli, N.; Girelli, D.; Olivieri, O.; Stranieri, C.; Trabetti, E.; Pizzolo, F.; Friso, S.; Tenuti, I.; Cheng, S.; Grow, M.A.; Pignatti, P.F.; Corrocher, R. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur. J. Clin. Invest., 2004, 34, 14-20.
40. Sanghera, D.K.; Aston, C.E.; Saha, N.; Kamboh, M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J. Hum. Genet., 1998, 62, 36-44.
41. Wang, X.Y.; Xue, Y.M.; Wen, S.J.; Zhang, N.L.; Ji, Z.; Pan, S.Y. The association of paraoxonase 2 gene C311S variant with ischemic stroke in Chinese type 2 diabetes mellitus patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi., 2003, 20, 215-219.
42. Janka, Z.; Juhasz, A.; Rimanoczy, A.A.; Boda, K.; Marki-Zay, J.; Kalman, J. Codon 311 (CysYSer) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol. Psychiatry., 2002, 7, 110-112.
43. Erlich, P.M.; Lunetta, K.L.; Cupples, L.A.; Huyck, M.; Green, R.C.; Baldwin, C.T.; Farrer, L.A. Polymorphisms in the PON gene cluster are associated with Alzheimer disease. Hum. Mol. Genet., 2006, 15, 77-85.
44. Draganov, D.I.; Teiber, J.F.; Speelman, A.; Osawa, Y.; Sunahara, R.; La, Du, B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res., 2005, 46, 1239-1247.
45. Teiber, J.F.; Draganov, D.I.; La, Du, B.N. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. Biochem. Pharmacol., 2003, 66, 887-896.
46. Campo, S.; Sardo, A.M.; Campo, G.M.; Avenoso, A.; Castaldo, M.; D'Ascola, A.; Giunta, E.; Calatroni, A.; Saitta, A. Identification of paraoxonase 3 gene (PON3) missense mutations in a population of southern Italy. Mutat. Res., 2004, 546, 75-80.
47. Sanghera, D.K.; Manzi, S.; Minster, R.L.; Shaw, P.; Kao, A. Bontempo F and Kamboh MI. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Ann. Hum. Genet., 2007, 72, 72-81.